BridgeBio Pharma, Inc. (BBIO)
BBIO Stock Price Chart
Explore BridgeBio Pharma, Inc. interactive price chart. Choose custom timeframes to analyze BBIO price movements and trends.
BBIO Company Profile
Discover essential business fundamentals and corporate details for BridgeBio Pharma, Inc. (BBIO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Jun 2019
Employees
725.00
Website
https://www.bridgebio.comCEO
Neil Kumar
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
BBIO Financial Timeline
Browse a chronological timeline of BridgeBio Pharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Apr 2026
Upcoming earnings on 18 Feb 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.69.
Earnings released on 5 Aug 2025
EPS came in at -$0.95 falling short of the estimated -$0.83 by -14.46%, while revenue for the quarter reached $110.57M , beating expectations by +1.97%.
Earnings released on 29 Apr 2025
EPS came in at -$0.88 surpassing the estimated -$1.00 by +12.00%, while revenue for the quarter reached $116.63M , beating expectations by +70.48%.
Earnings released on 20 Feb 2025
EPS came in at -$1.31 falling short of the estimated -$1.09 by -20.18%, while revenue for the quarter reached $5.88M , beating expectations by +45.62%.
Earnings released on 12 Nov 2024
EPS came in at -$0.86 surpassing the estimated -$1.03 by +16.50%, while revenue for the quarter reached $2.73M , missing expectations by -95.94%.
Earnings released on 1 Aug 2024
EPS came in at -$1.02 surpassing the estimated -$1.09 by +6.42%, while revenue for the quarter reached $2.17M , missing expectations by -39.27%.
Earnings released on 2 May 2024
EPS came in at -$0.05 surpassing the estimated -$0.40 by +87.50%, while revenue for the quarter reached $211.12M , beating expectations by +1.40K%.
Earnings released on 22 Feb 2024
EPS came in at -$0.96 falling short of the estimated -$0.95 by -1.05%, while revenue for the quarter reached $1.75M , missing expectations by -71.99%.
Earnings released on 2 Nov 2023
EPS came in at -$1.08 falling short of the estimated -$0.86 by -25.58%, while revenue for the quarter reached $4.09M , missing expectations by -3.97%.
Earnings released on 3 Aug 2023
EPS came in at -$0.98 falling short of the estimated -$0.86 by -13.95%, while revenue for the quarter reached $1.64M , missing expectations by -45.12%.
Earnings released on 4 May 2023
EPS came in at -$0.92 falling short of the estimated -$0.84 by -9.52%, while revenue for the quarter reached $1.83M , missing expectations by -45.82%.
Earnings released on 23 Feb 2023
EPS came in at -$0.87 falling short of the estimated -$0.86 by -1.16%, while revenue for the quarter reached $1.87M , missing expectations by -58.67%.
Earnings released on 3 Nov 2022
EPS came in at -$0.93 surpassing the estimated -$1.02 by +8.82%, while revenue for the quarter reached $338.00K , missing expectations by -91.73%.
Earnings released on 4 Aug 2022
EPS came in at -$0.81 surpassing the estimated -$0.92 by +11.96%, while revenue for the quarter reached $73.75M , beating expectations by +171.23%.
Earnings released on 5 May 2022
EPS came in at -$1.19 falling short of the estimated -$1.13 by -5.31%, while revenue for the quarter reached $1.69M , missing expectations by -63.92%.
Earnings released on 24 Feb 2022
EPS came in at -$1.01 falling short of the estimated -$0.83 by -21.69%, while revenue for the quarter reached $12.89M , missing expectations by -40.24%.
Earnings released on 4 Nov 2021
EPS came in at -$1.06 falling short of the estimated -$0.91 by -16.48%, while revenue for the quarter reached $2.34M , missing expectations by -84.48%.
Earnings released on 5 Aug 2021
EPS came in at -$0.66 surpassing the estimated -$0.93 by +29.03%, while revenue for the quarter reached $54.02M , beating expectations by +55.06%.
Earnings released on 6 May 2021
EPS came in at -$1.18 falling short of the estimated -$0.87 by -35.63%, while revenue for the quarter reached $462.00K , missing expectations by -96.87%.
Earnings released on 25 Feb 2021
EPS came in at -$1.01 falling short of the estimated -$0.86 by -17.44%, while revenue for the quarter reached $122.00K , missing expectations by -99.28%.
Earnings released on 5 Nov 2020
EPS came in at -$0.98 falling short of the estimated -$0.97 by -1.03%, while revenue for the quarter reached $8.13M , beating expectations by +6.52%.
BBIO Stock Performance
Access detailed BBIO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.